Below are the most recent publications written about "Neoplasm Grading" by people in Profiles.
-
Sangoi AR, Shahabi A, Hirsch MS, Kao CS, Deebajah M, Barletta JA, Paner GP, Smith SC, Grignon DJ, Comp?rat E, Amin MB, Maclean F, Shah RB, Iczkowski KA, Delprado W, Cheng L, Pan CC, McKenney JK, Ro JY, Khani F, Montironi R, Robinson BD, Al-Ahmadie H, Epstein JI, Trpkov K, Tretiakova M, Shen SS, Alanee S, Weight CJ, Akgul M, Williamson SR. Urothelial carcinoma in situ with "early papillary formation" vs "lateral spread/shoulder lesion" of prior high-grade noninvasive papillary urothelial carcinoma: A survey of pathologist and urologist interpretations. Am J Clin Pathol. 2025 Apr 19; 163(4):629-640.
-
Alvero AB, Wu S, Farrell A, Kim S, Wallbillich JJ, Winer I, Morris R, Spetzler D, Anderson ML, Puccini A, Jones NL, Herzog TJ, Thaker PH, Mor G, Gogoi RP. Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis. Gynecol Oncol. 2025 Mar; 194:71-79.
-
Goss LB, Liu M, Zheng Y, Guo B, Conti DV, Haiman CA, Kachuri L, Catalona WJ, Witte JS, Lin DW, Newcomb LF, Darst BF. Polygenic Risk Score and Upgrading in Patients With Prostate Cancer Receiving Active Surveillance. JAMA Oncol. 2025 Feb 01; 11(2):168-171.
-
Yadav VK, Sharma S, Maurya S, Singh RK, Saini J, Jain P, Patir R, Ahlawat S, Das S, Vaishya S, Agarwal S, Singh A, Gupta RK. Presence of Fragmented Intratumoral Thrombosed Microvasculature in the Necrotic and Peri-Necrotic Regions on SWI Differentiates IDH Wild-Type Glioblastoma From IDH Mutant Grade 4 Astrocytoma. J Magn Reson Imaging. 2025 Jul; 62(1):258-270.
-
Pierorazio PM, Kleinmann N, Shabsigh A, Hu B, Raman JD, Kaimakliotis H, Sankin A, Singla N, Meads A, Burger B, Raju S, Louie MJ, Chamie K, Weizer A, Schoenberg M. Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel. J Urol. 2025 Mar; 213(3):313-322.
-
Liss MA, Zeltser N, Zheng Y, Lopez C, Liu M, Patel Y, Yamaguchi TN, Eng SE, Tian M, Semmes OJ, Lin DW, Brooks JD, Wei JT, Klein EA, Tewari AK, Mosquera JM, Khani F, Robinson BD, Aasad M, Troyer DA, Kagan J, Sanda MG, Thompson IM, Boutros PC, Leach RJ. Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort. Cancer Epidemiol Biomarkers Prev. 2024 Nov 01; 33(11):1500-1511.
-
McIlvain G, Hayes LL, Walter AW, Averill LW, Kandula V, Johnson CL, Nikam RM. Mechanical properties of pediatric low-grade gliomas in children with and without neurofibromatosis type 1. Neuroradiology. 2024 Dec; 66(12):2301-2311.
-
Fine RE, Gilmore RC, Tomkovich KR, Dietz JR, Berry MP, Hernandez LE, Columbus KS, Seedman SA, Fisher CS, Han LK, Manahan ER, Hicks RD, Vaidya RP, Curcio LD, Sevrukov AB, Kenler AS, Taback B, Chen M, Miller ME, Gold L, Anglin BV, Aoun HD, Simmons RM, Feldman SM, Boolbol SK. Cryoablation Without Excision for Early-Stage Breast Cancer: ICE3 Trial 5-Year Follow-Up on Ipsilateral Breast Tumor Recurrence. Ann Surg Oncol. 2024 Oct; 31(11):7273-7283.
-
Pressler L, Pressler M. Focal Therapy in Grade Group 3 Prostate Cancer. Curr Urol Rep. 2024 Nov; 25(11):271-275.
-
Newcomb LF, Schenk JM, Zheng Y, Liu M, Zhu K, Brooks JD, Carroll PR, Dash A, de la Calle CM, Ellis WJ, Filson CP, Gleave ME, Liss MA, Martin F, McKenney JK, Morgan TM, Tretiakova MS, Wagner AA, Nelson PS, Lin DW. Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer. JAMA. 2024 06 25; 331(24):2084-2093.